What it's for (Indications)
- Albendazole, marketed under various brand names including Alfoz, is a broad-spectrum anthelmintic agent primarily indicated for the treatment of various parasitic worm infections.
- Its efficacy extends to both intestinal and systemic helminthiasis.
- Key indications include neurocysticercosis, a parasitic infection of the central nervous system caused by the larval form of the pork tapeworm *Taenia solium*, and hydatid disease (cystic and alveolar echinococcosis), caused by the larval stages of *Echinococcus granulosus* and *Echinococcus multilocularis*, respectively.
- Furthermore, it is effective against a range of intestinal nematode infections, such as ascariasis (roundworm), hookworm infections (Ancylostoma duodenale and Necator americanus), enterobiasis (pinworm/threadworm), trichuriasis (whipworm), strongyloidiasis, and clonorchiasis.
- Its use is crucial in endemic areas for mass drug administration programs aimed at controlling soil-transmitted helminth infections, significantly reducing morbidity associated with these parasitic diseases.
- The specific dosing and duration of treatment vary considerably depending on the type of parasitic infection, its severity, and the patient's individual clinical status, always requiring precise medical diagnosis and supervision.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of albendazole varies significantly depending on the specific parasitic infection, patient age, weight, and clinical condition. For neurocysticercosis, a common regimen involves administering 400 mg orally twice daily with meals for 8 to 30 days, often accompanied by corticosteroids to manage inflammatory reactions. In the treatment of hydatid disease, the typical adult dose is 400 mg twice daily with meals for 28-day cycles, followed by a 14-day albendazole-free interval, repeated for a total of 3 or more cycles, depending on the response and type of echinococcosis. For common intestinal helminthic infections like ascariasis, hookworm, or trichuriasis, a single oral dose of 400 mg is often sufficient. For enterobiasis, a single 400 mg dose is given, which may be repeated after two weeks to prevent re-infection. Strongyloidiasis and giardiasis may require longer courses, typically 400 mg once daily for 3 days. All doses should be taken with food, especially fatty meals, to enhance absorption. Pediatric dosing is often weight-based or follows specific age-related guidelines. Close medical supervision is essential to ensure appropriate dosing, monitor treatment efficacy, and manage potential side effects. |
Safety & Warnings
Common Side Effects
- Albendazole is generally well-tolerated, but like all medications, it can cause a range of side effects, which vary in incidence and severity.
- Common side effects often include gastrointestinal disturbances such as abdominal pain, nausea, vomiting, and diarrhea.
- Headaches and dizziness are also frequently reported.
- Less common but notable side effects include transient elevations in liver enzymes (transaminases), which typically normalize upon cessation of treatment.
- Dermatological reactions like rash, urticaria, and pruritus can occur.
- Hair loss (reversible alopecia) has been observed with prolonged use.
- More serious, albeit rare, adverse effects include hematologic abnormalities such as leukopenia (decreased white blood cell count), agranulocytosis, and pancytopenia, requiring careful monitoring of blood counts during extended therapy.
- Patients treated for neurocysticercosis may experience severe neurological symptoms (e.
- g.
- , seizures, increased intracranial pressure, focal neurological deficits) due to an inflammatory reaction to the dying parasites, which necessitates concomitant corticosteroid administration and vigilant neurological monitoring.
- Allergic reactions, including anaphylaxis, are possible but rare.
- Patients should be advised to report any unusual or severe symptoms to their healthcare provider immediately.
Serious Warnings
- Black Box Warning: While albendazole does not carry a formal FDA Black Box Warning, several serious safety concerns necessitate careful consideration and stringent patient monitoring, warranting a 'Serious Warnings' section. **Myelosuppression:** Albendazole therapy, particularly with higher doses or prolonged regimens, can lead to significant bone marrow suppression, manifesting as leukopenia, agranulocytosis, pancytopenia, or, rarely, aplastic anemia. Complete blood counts (CBCs) including differential and platelet count should be performed at baseline and monitored every two weeks during prolonged treatment. Treatment should be discontinued if clinically significant decreases in blood cell counts occur. **Hepatotoxicity:** Transient elevations in liver enzymes (transaminases) are common and usually reversible upon discontinuation. However, severe hepatotoxicity has been reported. Liver function tests (LFTs) should be performed at baseline and periodically monitored during therapy, especially in patients with pre-existing liver impairment or those receiving prolonged courses. **Neurocysticercosis-related Inflammatory Reactions:** In patients treated for neurocysticercosis, the destruction of parasites by albendazole can induce an inflammatory response around dying cysts in the brain, potentially leading to increased intracranial pressure, seizures, and focal neurological deficits. Patients should be closely monitored for neurological symptoms, and corticosteroids (e.g., dexamethasone) are often co-administered to mitigate these inflammatory reactions. Anticonvulsant therapy may also be required. **Teratogenicity:** Albendazole has demonstrated teratogenic effects in animal studies. It is contraindicated in pregnancy, especially during the first trimester. Women of childbearing potential must use effective contraception during treatment and for at least one month following the last dose, with a negative pregnancy test confirmed prior to initiation of therapy. These risks underscore the importance of individualized patient assessment, thorough monitoring, and expert medical supervision throughout albendazole therapy.
- Several critical warnings and precautions are associated with albendazole use.
- Patients with known hypersensitivity to albendazole or other benzimidazole derivatives should avoid this medication.
- Albendazole has been shown to be teratogenic in animal studies, therefore it is contraindicated in pregnancy, particularly during the first trimester.
- Women of childbearing potential should undergo a pregnancy test prior to initiation of therapy and use effective contraception during and for at least one month after treatment.
- Caution is advised in patients with pre-existing hepatic impairment due to the drug's metabolism in the liver and the potential for liver enzyme elevations; liver function tests should be monitored periodically, especially during prolonged treatment.
- Renal impairment does not significantly alter albendazole pharmacokinetics, but careful monitoring is still warranted.
- Bone marrow suppression, including leukopenia, pancytopenia, and aplastic anemia, has been reported, particularly with higher doses and longer durations of therapy; complete blood counts should be performed at baseline and every two weeks during treatment.
- In patients with neurocysticercosis, the inflammatory response to dying cysts can exacerbate pre-existing neurological symptoms or induce new ones, necessitating concomitant corticosteroid therapy and vigilant neurological monitoring.
- This medication should only be prescribed after a definitive diagnosis of parasitic infection has been established.
How it Works (Mechanism of Action)
Albendazole exerts its anthelmintic effects primarily by interfering with the parasite's cellular structure and metabolic functions. As a benzimidazole carbamate, its principal mechanism of action involves binding to the parasite's beta-tubulin, a structural protein essential for the formation of microtubules. This high-affinity binding to helminthic beta-tubulin, which is selectively greater than its binding to mammalian beta-tubulin, inhibits microtubule polymerization. Microtubules are critical components of various cellular structures, including the cytoskeleton, mitotic spindle, and cellular transport systems in helminths. The disruption of microtubule formation leads to the irreversible inhibition of glucose uptake and utilization by the parasite, resulting in the depletion of glycogen stores. This energy deprivation impairs vital metabolic processes, including adenosine triphosphate (ATP) production, which is crucial for the parasite's survival and reproduction. Consequently, the affected helminth experiences immobilization, reduced motility, and ultimately starvation and death. Albendazole is rapidly metabolized in the liver to its primary active metabolite, albendazole sulfoxide, which is responsible for most of its systemic anthelmintic activity. This metabolite then undergoes further oxidation to albendazole sulfone or hydrolytic cleavage to albendazole 2-amino sulfone.